Companies › Aperta Biosciences
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| APT-001 topical ophthalmic ointment (spinosad 1.8%) Spinosad is a natural insecticide/acaricide that kills parasites and mites; mechanism in b | – | Phase 2 | Blepharitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06720896 | APT-001 topical ophthalmic ointment (spinosad 1.8%) | Phase 2 | Blepharitis | Ophthalmology | Jul 2026 |
No annotated target.
–
Qlaris Bio Jiangsu Jingze Biopharmaceutical ONL Therapeutics BioTheraVision Vantage Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.